Viridian Therapeutics, Inc.\DE.
- VRDN · Nasdaq
- Pharmaceutical Preparations
- Waltham, MA
- 252 employees
- CIK 0001590750
Updated from SEC filings through
Top things to know
Executives
- Steve Mahoney President and Chief Executive Officer of Viridian Therapeutics 8-K, 2026-11-04
- Stephen F. Mahoney President and CEO 4/A, 2026-03-09
- Stephen Mahoney President & Chief Executive Officer 10-K, 2026-02-26
-
Seth Harmon Chief Financial Officer 4/A, 2026-03-09 -
Jennifer Tousignant Chief Legal Officer 4, 2026-08-20 -
Radhika Tripuraneni Chief Medical Officer 4, 2026-08-18
What leadership is saying
“We are highly encouraged by the strength of Lumvoa’s early launch in TED, which has exceeded expectations”
Earnings press release (8-K Ex. 99.1), filed November 4, 2026
Viridian Therapeutics, Inc.\DE is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Waltham, MA. It trades as VRDN on Nasdaq. Revenue was $70.8M in the fiscal year ending December 31, 2025, +23359.9% from the year before. It reported about 252 employees. Steve Mahoney is President and Chief Executive Officer of Viridian Therapeutics.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $70.8M 10-K, 2026-02-26 | $302K 10-K, 2026-02-26 | $314K 10-K, 2026-02-26 | $1.8M 10-K, 2025-03-03 | $3.0M 10-K, 2024-02-27 |
| Operating income | -$363M 10-K, 2026-02-26 | -$299M 10-K, 2026-02-26 | -$254M 10-K, 2026-02-26 | -$134M 10-K, 2025-03-03 | -$79.7M 10-K, 2024-02-27 |
| SG&A | $95.3M 10-K, 2026-02-26 | $61.1M 10-K, 2026-02-26 | $95.0M 10-K, 2026-02-26 | $35.2M 10-K, 2025-03-03 | $25.8M 10-K, 2024-02-27 |
| Net income | -$343M 10-K, 2026-02-26 | -$270M 10-K, 2026-02-26 | -$238M 10-K, 2026-02-26 | -$130M 10-K, 2025-03-03 | -$79.4M 10-K, 2024-02-27 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Steve Mahoney President and Chief Executive Officer | President and Chief Executive Officer of Viridian Therapeutics | 8-K, 2026-11-04 |
| Stephen F. Mahoney | President and CEO | 4/A, 2026-03-09 |
| Stephen Mahoney | President & Chief Executive Officer | 10-K, 2026-02-26 |
| Seth Harmon | Chief Financial Officer | 4/A, 2026-03-09 |
| Jennifer Tousignant | Chief Legal Officer | 4, 2026-08-20 |
| Radhika Tripuraneni Chief Medical Officer & Board Member | Chief Medical Officer | 4, 2026-08-18 |
| Thomas W. Beetham Chief Operating Officer at Viridian Therapeutics | Chief Operating Officer | 4/A, 2026-03-09 |
| Thomas Beetham | Chief Operating Officer | 10-K, 2026-02-26 |
| Tomas Kiselak | Board member (per proxy) bio: Compensation Committee | DEF 14A, 2026-04-17 |
| Arlene M. Morris | Board member (per proxy) bio: Independent Director | DEF 14A, 2026-04-17 |
| Chris Cain, Ph.D. | Board member (per proxy) bio: Independent Director | DEF 14A, 2026-04-17 |
| Jeff Ajer | Board member (per proxy) bio: Independent Director | DEF 14A, 2026-04-17 |
| Jennifer K. Moses | Board member (per proxy) bio: Independent Director | DEF 14A, 2026-04-17 |
| Sarah Gheuens, M.D., Ph.D. | Board member (per proxy) bio: Independent Director | DEF 14A, 2026-04-17 |
What Viridian Therapeutics, Inc.\DE does
We are a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases. We target therapeutic areas in which current treatments leave room for improvements in efficacy, safety, and/or dosing convenience. We believe there is significant potential in these areas, for better medicines that address unmet needs, improve outcomes, and expand treatment options for patients.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 113.6 million (as of November 2, 2026) | 10-Q, November 4, 2026 |
|---|---|---|
| Public float | $943M (as of June 30, 2025) | 10-K, February 26, 2026 |
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, November 4, 2026 |
| Latest proxy statement | Meeting June 2, 2026 (filed April 17, 2026) | DEF 14A, April 17, 2026 |
| Auditor | Kpmg LLP (Boston, Massachusetts) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| August 19, 2026 | Jennifer Tousignant Chief Legal Officer | Sale | 14,212 | $348K | Form 4, August 20, 2026 |
| May 11, 2026 | Funds Management LLC Fairmount Director | Buy | 1,176,470 | $20.0M | Form 4, May 13, 2026 |
| May 11, 2026 | Healthcare Fund GP LLC Fairmount II Director | Buy | 1,176,470 | $20.0M | Form 4, May 13, 2026 |
| May 11, 2026 | Healthcare Fund L.P. Fairmount II Director | Buy | 1,176,470 | $20.0M | Form 4, May 13, 2026 |
| December 31, 2025 | Jennifer Tousignant Chief Legal Officer | Sale | 2,272 | $71K | Form 4, January 2, 2026 |
| October 23, 2025 | Healthcare Fund L.P. Fairmount II Director | Buy | 454,545 | $10.0M | Form 4, October 27, 2025 |
| October 23, 2025 | Funds Management LLC Fairmount Director | Buy | 454,545 | $10.0M | Form 4, October 27, 2025 |
| October 23, 2025 | Healthcare Fund GP LLC Fairmount II Director | Buy | 454,545 | $10.0M | Form 4, October 27, 2025 |
Recent 8-K events
- 8-K filed 2026-11-04
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-08-06
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-06-29
- Item 7.01 Regulation FD disclosure
- Item 8.01 Other events
- 8-K filed 2026-06-03
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-28
- Item 1.02 Termination of a material definitive agreement
- 8-K filed 2026-05-26
- Item 1.01 Entry into a material definitive agreement
- 8-K filed 2026-05-11
- Item 1.01 Entry into a material definitive agreement
- Item 2.03 Creation of a direct financial obligation
- Item 8.01 Other events
- 8-K filed 2026-05-05
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-05-05
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-03-30
- Item 7.01 Regulation FD disclosure
Frequently asked questions about Viridian Therapeutics, Inc.\DE
- What does Viridian Therapeutics, Inc.\DE do?
- In its own words, from Item 1 of its 10-K: "We are a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases. We target therapeutic areas in which current treatments leave room for improvements in efficacy, safety, and/or dosing convenience. We believe there is significant potential in these areas, for better medicines that address unmet needs, improve outcomes, and expand treatment options for patients."
- What is Viridian Therapeutics, Inc.\DE's revenue?
- $70.8M for the fiscal year ending December 31, 2025, from its 10-K filed February 26, 2026.
- Is Viridian Therapeutics, Inc.\DE profitable?
- Viridian Therapeutics, Inc.\DE reported net income of -$343M for the fiscal year ending December 31, 2025.
- How many employees does Viridian Therapeutics, Inc.\DE have?
- About 252 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Viridian Therapeutics, Inc.\DE?
- Steve Mahoney, President and Chief Executive Officer of Viridian Therapeutics, as named in a 8-K filed November 4, 2026.
- Who is the CFO of Viridian Therapeutics, Inc.\DE?
- Seth Harmon, Chief Financial Officer, as named in a 4/A filed March 9, 2026.
- Where is Viridian Therapeutics, Inc.\DE headquartered?
- Waltham, MA.
- What is Viridian Therapeutics, Inc.\DE's stock ticker?
- VRDN on Nasdaq.
- What industry is Viridian Therapeutics, Inc.\DE in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Viridian Therapeutics, Inc.\DE's website?
- viridiantherapeutics.com.
- When does Viridian Therapeutics, Inc.\DE report earnings next?
- February 5, 2027. Source: estimate_8k_pattern.
- Is Viridian Therapeutics, Inc.\DE a public company?
- Yes. Viridian Therapeutics, Inc.\DE files with the SEC under CIK 0001590750 and trades as VRDN.
- Who audits Viridian Therapeutics, Inc.\DE?
- Kpmg LLP, Boston, Massachusetts, as named in its latest annual report (10-K).
- How many shares of Viridian Therapeutics, Inc.\DE are outstanding?
- 113.6 million shares as of November 2, 2026, from its 10-Q filed November 4, 2026.
- What is Viridian Therapeutics, Inc.\DE's public float?
- $943M as of June 30, 2025, as reported on the cover of its 10-K filed February 26, 2026.
- How many business segments does Viridian Therapeutics, Inc.\DE report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 4, 2026.
- When is Viridian Therapeutics, Inc.\DE's annual shareholder meeting?
- June 2, 2026, per its proxy statement (DEF 14A) filed April 17, 2026.
- Have Viridian Therapeutics, Inc.\DE insiders traded stock recently?
- Since October 23, 2025, officers and directors reported 2 open-market sales worth about $419K and 6 purchases worth about $90.0M on Forms 4 and 5. The most recent: Jennifer Tousignant (Chief Legal Officer) sold 14,212 shares on August 19, 2026.